000282556 001__ 282556
000282556 005__ 20251218103442.0
000282556 0247_ $$2doi$$a10.1038/s41398-025-03677-w
000282556 0247_ $$2pmid$$apmid:41257955
000282556 0247_ $$2pmc$$apmc:PMC12644748
000282556 037__ $$aDZNE-2025-01319
000282556 041__ $$aEnglish
000282556 082__ $$a610
000282556 1001_ $$aSu, Julia$$b0
000282556 245__ $$aHeterogeneity of anti-Caspr2 antibodies: specificity and pathogenicity.
000282556 260__ $$aLondon$$bNature Publishing Group$$c2025
000282556 3367_ $$2DRIVER$$aarticle
000282556 3367_ $$2DataCite$$aOutput Types/Journal article
000282556 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764680674_28229
000282556 3367_ $$2BibTeX$$aARTICLE
000282556 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282556 3367_ $$00$$2EndNote$$aJournal Article
000282556 520__ $$aMaternal anti-Caspr2 (Contactin-associated protein-like 2) antibodies have been associated with increased risk for autism spectrum disorder (ASD). Previous studies have shown that in utero exposure to anti-Caspr2 antibodies results in a phenotype with ASD-like features in male mice. Here we ask whether four newly generated antibodies against Caspr2 are pathogenic to the developing fetal brain and whether they function through similar means. Our results show that these novel anti-Caspr2 antibodies recognize different epitopes of Caspr2. In utero exposure to these antibodies elicits differential behavioral phenotypes in male offspring, as demonstrated in the social interaction task, as well as phenotypic alterations in the open-field and light-dark tasks. These results demonstrate variability in the antigenic specificity and pathogenicity of anti-Caspr2 antibodies which may have clinical implications.
000282556 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282556 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282556 650_7 $$2NLM Chemicals$$aNerve Tissue Proteins
000282556 650_7 $$2NLM Chemicals$$aMembrane Proteins
000282556 650_7 $$2NLM Chemicals$$aAutoantibodies
000282556 650_7 $$2NLM Chemicals$$aCNTNAP2 protein, mouse
000282556 650_2 $$2MeSH$$aAnimals
000282556 650_2 $$2MeSH$$aNerve Tissue Proteins: immunology
000282556 650_2 $$2MeSH$$aMale
000282556 650_2 $$2MeSH$$aFemale
000282556 650_2 $$2MeSH$$aMice
000282556 650_2 $$2MeSH$$aAutism Spectrum Disorder: immunology
000282556 650_2 $$2MeSH$$aMembrane Proteins: immunology
000282556 650_2 $$2MeSH$$aPregnancy
000282556 650_2 $$2MeSH$$aAutoantibodies: immunology
000282556 650_2 $$2MeSH$$aPrenatal Exposure Delayed Effects: immunology
000282556 650_2 $$2MeSH$$aBehavior, Animal
000282556 650_2 $$2MeSH$$aBrain: immunology
000282556 650_2 $$2MeSH$$aBrain: embryology
000282556 650_2 $$2MeSH$$aHumans
000282556 7001_ $$aGupta, Rohan$$b1
000282556 7001_ $$0P:(DE-2719)2812820$$avan Hoof, Scott$$b2$$udzne
000282556 7001_ $$0P:(DE-2719)2811468$$aKreye, Jakob$$b3
000282556 7001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b4
000282556 7001_ $$00000-0002-0634-8118$$aSpielman, Benjamin$$b5
000282556 7001_ $$00000-0002-5262-3053$$aBrimberg, Lior$$b6
000282556 7001_ $$00000-0002-1098-1848$$aVolpe, Bruce T$$b7
000282556 7001_ $$00000-0003-0270-2308$$aHuerta, Patricio T$$b8
000282556 7001_ $$00000-0002-3250-3804$$aDiamond, Betty$$b9
000282556 773__ $$0PERI:(DE-600)2609311-X$$a10.1038/s41398-025-03677-w$$gVol. 15, no. 1, p. 498$$n1$$p498$$tTranslational Psychiatry$$v15$$x2158-3188$$y2025
000282556 8564_ $$uhttps://pub.dzne.de/record/282556/files/DZNE-2025-01319.pdf$$yOpenAccess
000282556 8564_ $$uhttps://pub.dzne.de/record/282556/files/DZNE-2025-01319.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000282556 909CO $$ooai:pub.dzne.de:282556$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000282556 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000282556 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811468$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000282556 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000282556 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282556 9141_ $$y2025
000282556 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000282556 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000282556 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL PSYCHIAT : 2022$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:46:03Z
000282556 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:46:03Z
000282556 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000282556 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:46:03Z
000282556 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bTRANSL PSYCHIAT : 2022$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000282556 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000282556 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000282556 980__ $$ajournal
000282556 980__ $$aVDB
000282556 980__ $$aUNRESTRICTED
000282556 980__ $$aI:(DE-2719)1810003
000282556 9801_ $$aFullTexts